I think the best outcome here for MSB with the FDA is it will ask MSB to do another trial.
In teerms of market reaction, the AFR reported that While one analyst called the news “a watershed moment not just for Mesoblast, but for the industry”, other market watchers were sceptical about the trial not meeting the primary endpoint, as well as the very late data release.
They needed the time to massage the bad news is my take.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-223
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |